Aktienanalyse zu Senseonics Holdings Inc (SENS)SENSSenseonics Holdings Inc

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Currently, Senseonics Holdings Inc is not a strong buy due to its low RSI of 27.789, indicating oversold conditions, and a forward P/E ratio of 21.0084, which suggests the stock may be overvalued relative to its earnings potential. The recent insider activity shows no significant trends, and while hedge funds are buying with a 1675.05% increase in buying amount, the overall market sentiment remains cautious. The main risk is the projected loss of $0.49 per share in the next earnings report, which could further impact investor confidence.

4 analysts cover SENS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.70.